The Quest to Save American-Made Antibiotics
USAntibiotics's plant in Tennessee is one of the last plants in the United States that makes amoxicillin, the crucial antibiotic that has been in shortage in some forms since 2022. But the plant isn’t breaking even, financially. WSJ’s Liz Essley Whyte reports on why it is so hard for American-made generic drugs…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like The Journal. →
How Eli Lilly Became the First Pharma Company to Reach a $1 Trillion Market Cap
Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs
Can Trump Cut Prescription Prices?
Why are drug prices so high? Investigating the outdated US patent system | Priti Krishtel
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.